Published in J Pathol on May 01, 2010
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
The critical role of IL-34 in osteoclastogenesis. PLoS One (2011) 1.14
Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis (2011) 1.12
IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ. PLoS One (2013) 1.09
Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther (2012) 1.05
Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg (2012) 1.00
Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol (2011) 1.00
An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations. J Bone Miner Res (2013) 0.97
The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation. PLoS One (2013) 0.90
Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. PLoS One (2013) 0.90
Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88
Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. J Immunol Res (2014) 0.86
Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci U S A (2012) 0.86
Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci (2014) 0.85
IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest (2015) 0.84
Divergent antiviral roles of amphibian (Xenopus laevis) macrophages elicited by colony-stimulating factor-1 and interleukin-34. J Leukoc Biol (2014) 0.84
IL-1β and TNFα promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts. Mediators Inflamm (2014) 0.83
Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. Rheumatol Int (2014) 0.78
Amphibian macrophage development and antiviral defenses. Dev Comp Immunol (2015) 0.77
Proteoglycans and osteolysis. Methods Mol Biol (2012) 0.77
Interleukin-34 induces monocytic-like differentiation in leukemia cell lines. Int J Biochem Mol Biol (2015) 0.77
Integrative genomic analyses of a novel cytokine, interleukin-34 and its potential role in cancer prediction. Int J Mol Med (2014) 0.76
Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology (2016) 0.76
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica (2007) 3.23
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev (2004) 2.72
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev (2004) 2.35
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Continuous peripheral nerve blocks with stimulating catheters. Reg Anesth Pain Med (2003) 2.23
Cerebral hyperemia during recovery from general anesthesia in neurosurgical patients. Anesth Analg (2002) 2.08
Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol (2010) 2.08
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood (2007) 1.91
Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood (2005) 1.86
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation (2006) 1.75
Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int (2007) 1.65
Absence of Nodal signaling promotes precocious neural differentiation in the mouse embryo. Dev Biol (2006) 1.61
Mechanisms of bone repair and regeneration. Trends Mol Med (2009) 1.61
Temporal arteritis associated with systemic necrotizing vasculitis. J Rheumatol (2003) 1.57
Provocative sacroiliac joint maneuvers and sacroiliac joint block are unreliable for diagnosing sacroiliac joint pain. Joint Bone Spine (2006) 1.54
IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol (2007) 1.46
Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med (2007) 1.43
Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) (2013) 1.42
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. Plast Reconstr Surg (2016) 1.40
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Useful side handle for holding needle during ultrasound-guided regional anesthesia. Reg Anesth Pain Med (2009) 1.38
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Initiation of gastrulation in the mouse embryo is preceded by an apparent shift in the orientation of the anterior-posterior axis. Curr Biol (2004) 1.35
Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc Natl Acad Sci U S A (2004) 1.33
PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet (2013) 1.33
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer (2005) 1.30
The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev (2008) 1.30
Development and validation of a perioperative satisfaction questionnaire. Anesthesiology (2005) 1.29
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells (2012) 1.29
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res (2007) 1.26
Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev (2002) 1.24
Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther (2007) 1.23
Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J (2005) 1.21
Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A (2004) 1.21
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood (2007) 1.20
Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med (2004) 1.19
Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J Immunol (2009) 1.19
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res (2010) 1.12
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol (2009) 1.09
High rate of ceramic sandwich liner fracture. Clin Orthop Relat Res (2012) 1.09
Proteoglycans: key partners in bone cell biology. Bioessays (2007) 1.07
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation. Stem Cells (2006) 1.07
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging (2009) 1.07
Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol (2009) 1.05
Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation (2008) 1.04
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer (2006) 1.04
Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem (2008) 1.03
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone (2006) 1.02
Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev (2013) 1.02
Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol (2012) 1.02
Identification of a new member of the CD20/FcepsilonRIbeta family overexpressed in tolerated allografts. Am J Transplant (2005) 1.02
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res (2009) 1.01
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) 1.00
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging (2010) 0.99
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. J Med Genet (2012) 0.98
Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One (2012) 0.98
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res (2004) 0.98
Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology (2014) 0.96
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep (2007) 0.96
Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis (2011) 0.96
ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res (2011) 0.96
Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy (2014) 0.96
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res (2010) 0.96
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol (2006) 0.95
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther (2009) 0.94
In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet (2012) 0.94
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer (2014) 0.94
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer (2014) 0.94
Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine (2010) 0.93
Clonal and molecular analysis of the prospective anterior neural boundary in the mouse embryo. Development (2012) 0.92
Systemic vasculitis with lymphocytic temporal arteritis and Toxocara canis infection. Arch Intern Med (2002) 0.92
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res (2008) 0.91
Intragenic CAMTA1 rearrangements cause non-progressive congenital ataxia with or without intellectual disability. J Med Genet (2012) 0.91
Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients. Anesth Analg (2003) 0.91
First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med (2009) 0.90